Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8296791 | 0.94 | HSD11B1 (0.66) | HSD11B1BRD3OPRM1OPRK1OPRL1 | |
| SCHEMBL4882143 | 0.91 | DRD2 (0.56) | HSD11B1BRD3OPRM1OPRL1SLC6A4 | |
| SCHEMBL8618496 | 0.88 | CYP1A2 (0.63) | HSD11B1HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL12127418 | 0.87 | KDM4E (0.49) | HSD11B1HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL892836 | 0.87 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1AHTR1D | |
| SCHEMBL6212815 | 0.87 | HTR1D (0.62) | HSD11B1HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL30567991 | 0.87 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1AHTR1D | |
| SCHEMBL28380406 | 0.86 | MTNR1A (0.61) | HSD11B1HTR1ASLC6A4ALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL1703941 | 0.86 | OPRM1 (0.52) | OPRM1OPRK1OPRL1HTR1AHTR1D | |
| SCHEMBL2263846 | 0.84 | CCR2 (0.52) | HSD11B1HTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386269-A | Novel heterocyclic compound | 豪夫迈·罗氏有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-106045967-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-106045966-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-1945213-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-23 | — | — | EP | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| WO-2002008223-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-31 | — | — | WO | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| CN-1250445-A | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-12 | — | — | CN | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| CN-1209807-A | 1-pyrazol-3-yl-ethyl-4-indol-3-yl piperdine as medicine acting on central nervous system | MERCK PATENT AG (DE) | 1999-03-03 | — | — | CN | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | HSD11B1 1138/4885BRD3 2732/4885OPRM1 549/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | HSD11B1 1138/4885BRD3 2732/4885OPRM1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.